Replimune Group Stock Forecast, Price & News

+0.88 (+2.64 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume329,202 shs
Average Volume355,646 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive REPL News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

Replimune Group logo

About Replimune Group

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.39 out of 5 stars

Medical Sector

173rd out of 1,309 stocks

Biological Products, Except Diagnostic Industry

21st out of 179 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Replimune Group (NASDAQ:REPL) Frequently Asked Questions

Is Replimune Group a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Replimune Group stock.
View analyst ratings for Replimune Group
or view top-rated stocks.

What stocks does MarketBeat like better than Replimune Group?

Wall Street analysts have given Replimune Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Replimune Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Replimune Group

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) announced its quarterly earnings results on Thursday, May, 20th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.41).
View Replimune Group's earnings history

How has Replimune Group's stock been impacted by Coronavirus (COVID-19)?

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REPL shares have increased by 186.9% and is now trading at $34.23.
View which stocks have been most impacted by COVID-19

What price target have analysts set for REPL?

8 equities research analysts have issued twelve-month price targets for Replimune Group's stock. Their forecasts range from $48.00 to $67.00. On average, they expect Replimune Group's stock price to reach $56.00 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price.
View analysts' price targets for Replimune Group
or view top-rated stocks among Wall Street analysts.

Who are Replimune Group's key executives?

Replimune Group's management team includes the following people:
  • Mr. Philip Astley-Sparke, CEO & Director (Age 50, Pay $613.95k)
  • Dr. Robert Coffin, Founder, Pres, Chief R&D Officer and Director (Age 56, Pay $725.79k)
  • Ms. Jean M. Franchi, Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer (Age 55, Pay $470.87k)
  • Dr. Pamela Esposito Ph.D., Chief Bus. Officer (Age 46, Pay $464.63k)
  • Dr. Colin A. Love, Chief Operating Officer (Age 63)
  • Dr. Andrea Pirzkall M.D., Chief Medical Officer (Age 51)
  • Ms. Tanya N. Lewis M.S., Chief Devel. Operations Officer (Age 50)
  • Mr. Sushil Patel Ph.D., Chief Commercial Officer

Who are some of Replimune Group's key competitors?

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a variety of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (1.94%), Emerald Mutual Fund Advisers Trust (1.61%), Emerald Advisers LLC (1.57%), Alliancebernstein L.P. (0.06%), Dupont Capital Management Corp (0.02%) and Arizona State Retirement System (0.01%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends for Replimune Group

Which institutional investors are selling Replimune Group stock?

REPL stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Victory Capital Management Inc., and Arizona State Retirement System. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, and Robert Coffin.
View insider buying and selling activity for Replimune Group
or view top insider-selling stocks.

Which institutional investors are buying Replimune Group stock?

REPL stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Dupont Capital Management Corp, and Lindbrook Capital LLC. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv LP Omega, and Jason P Rhodes.
View insider buying and selling activity for Replimune Group
or or view top insider-buying stocks.

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $34.23.

How much money does Replimune Group make?

Replimune Group has a market capitalization of $1.60 billion. The company earns $-80,870,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

How many employees does Replimune Group have?

Replimune Group employs 152 workers across the globe.

What is Replimune Group's official website?

The official website for Replimune Group is

Where are Replimune Group's headquarters?

Replimune Group is headquartered at 500 Unicorn Park, WOBURN MA, 01801.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.